Produced in Partnership with OpentronsApr 17 2024Reviewed by Louis Castel
The 21st century is increasingly being termed the Century of Biology, with breakthroughs occurring at unrecognizable speed. Major discoveries have led to real-world applications in numerous fields, including everything from personalized medicine to environmental conservation.
Next-generation sequencing and CRISPR-Cas9 started this technological revolution. The addition of artificial intelligence and a substantial number of high-throughput methods will exponentially increase the speed of progress. As scientific breakthroughs are made, scientists from companies of all sizes become more competitive in applying them.
Image Credit: Romix Image/Shutterstock.com
Successful innovators will need an original idea and the early adoption of technologies to achieve the vision of changing the world. They will have to meet the pressures to develop and commercialize their idea.
A company should consider future needs by raising its trajectory, applying forward-thinking, and adopting technology early. This could be the route to receiving continued funding and eventual commercialization ahead of its competitors.
Early-stage biotech companies also need to secure the next round of funding to begin new phases of research or growth. The clock resets with another set of goals after every round of new investment.
Although for some, this may seem like a race, the quality of the project and the ability to be prepared for the next phase are just as important as obtaining defined progress markers.
Companies must thus move quickly before being outpaced by a competitor or running out of money. They must ensure that investors are confident in their credibility and reproducibility to finance their future growth.
Machines are tireless, fast, and accurate. We are exploring unknown biology, and some of these explorations are across such a breadth of parameters, including combinations, that exploring them manually would be a waste of scientific minds.1
Retro Biosciences
Summary
Early-stage biotechnology companies are faced with a unique and challenging existence. Although delivering scientific results within tight deadlines seems essential for survival, experienced entrepreneurs recognize that this argument falls short when targets are achieved, but additional funding remains elusive.
Investors review an endless selection of companies looking for funding. Potential candidates must effectively demonstrate that they offer more than their recent scientific results.
Startup companies can distinguish themselves from the field and be positioned for success by demonstrating speed, scientific rigor, efficiency, and preparedness for the future.
References and Further Reading
- (Retro Biosciences, n.d) https://opentrons.com/customer-stories/retro-biosciences-sc-rnaseq/
About Opentrons
Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data. That's why we started Opentrons.
We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.